Company Profile

Enzon Pharmaceuticals Inc (AKA: Enzon Inc)
Profile last edited on: 12/14/2023      CAGE: 46NF7      UEI: C5NMBK4QPEV1

Business Identifier: NO Business Identifier is currently available for this company.
Year Founded
1983
First Award
1983
Latest Award
1997
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

20 Kingsbridge Road
Piscataway, NJ 08854
   (732) 980-4500
   investor@enzon.com
   www.enzon.com
Location: Multiple
Congr. District: 06
County: Middlesx

Public Profile

In February 2003, NPS Pharmaceuticals (Nasdaq: NPSP) acquired Enzon. NPS was itself previously an SBIR involved firm. Enzon is a biopharmaceutical company developing, manufacturing and marketing enhanced therapeutics for life-threatening diseases through the application of its proprietary technologies proprietary PEG (polyethelene glycol) - process enhances existing pharmaceuticals by attaching a nonreactive polymer. The modified drug then avoids the immune system's radar and lives in the blood longer, increasing effectiveness. FDA-approved products include Oncaspar, used to treat leukemia, and Adagen, an enzyme-replacement therapy for a rare, severe immunodeficiency commonly known as the "Bubble Boy Disease." Other PEG products in Enzon's pipeline include possible treatments for hepatitis C and for some types of cancers and tumors. It has marketing and research pacts with several leading drug companies, including Rhone-Poulenc Rohrer and Schering-Plough

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
500+
Revenue Range
Over 50M
VC funded?
Yes
Public/Private
Publicly Traded
Stock Info
OTC : ENZN
IP Holdings
150-249

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
1997 2 NIH $596,500
Project Title: Mammalian Peg Uricase for Therapy of Intractable Gout
1988 2 NIH $550,000
Project Title: Therapeutic enzymes for diseases involving active oxygen
1987 1 NIH $50,000
Project Title: Amino acid degrading enzymes as anticancer agents
1986 1 NIH $50,000
Project Title: Therapeutic uricase for uric acid induced pathologies
1985 1 Army $78,625
Project Title: Therapeutic rhodanese for cyanide poisoning

Key People / Management

  Arthur J Higgins

  Frank F Davis

  Michael S Hershfield

  Dennis Rodrigues

Company News

There are no news available.